Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 11/20 | 0.49 |
| ▸ | FLT4 | P35916 | 7/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041550 | 0.92 | PTK2 (0.51) | PTK2FLT4KDR | |
| SCHEMBL16511400 | 0.92 | PTK2 (0.51) | PTK2FLT4KDR | |
| SCHEMBL15041548 | 0.91 | PTK2 (0.51) | PTK2FLT4KDRJAK2BRD4 | |
| SCHEMBL15036203 | 0.89 | BTK (0.51) | PTK2FLT4KDRJAK2BRD4 | |
| SCHEMBL15041899 | 0.87 | PTK2 (0.53) | PTK2 | |
| SCHEMBL15041546 | 0.85 | WEE1 (0.41) | PTK2BTK | |
| SCHEMBL15041551 | 0.84 | PAK3 (0.52) | PTK2JAK2BRD4JAK1BRD2 | |
| SCHEMBL15036173 | 0.83 | CDK4 (0.45) | PTK2KDRJAK2BRD4JAK1 | |
| SCHEMBL15041734 | 0.83 | MAP4K3 (0.39) | PTK2FLT4KDR | |
| SCHEMBL15041541 | 0.83 | PTK2 (0.53) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680099-B2 | 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130245012-A1 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2011156786-A2 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245012-A1 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | PTK2 80/4885FLT4 1979/4885KDR 1998/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PTK2 12/4885FLT4 1741/4885KDR 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.